MYDAYIS

Peak

dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, and amphetamine sulfate

Takeda
NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
8/100

Mechanism of Action

non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.

Indications (2)

Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 yearsolder

Loss of Exclusivity

LOE Date
Aug 24, 2029
42 months away
Patent Expiry
Aug 24, 2029

Patent Records (2)

Patent #ExpiryTypeUse Code
9173857
May 12, 2026
U-2025
8846100
Aug 24, 2029
Product
—
Company
Takeda
Takeda
TOKYO, Japan
1373 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers